Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Pain
RCT	360 children aged 12–17 years In review	Complete pain relief at 2 hours 48/149 (32%) with rizatriptan 40/142 (28%) with placebo	P = 0.47		Not significant
RCT	360 children aged 12–17 years In review	Partial pain relief at 2 hours 98/149 (66%) with rizatriptan 80/142 (56%) with placebo	P = 0.08		Not significant
RCT	791 children aged 6–17 years (randomised at Stage 2 following a placebo run-in period [Stage 1] – see Further information on studies)	Pain freedom (defined as reduction in headache pain from moderate or severe to no pain on the 5-Face Pain Scale) at 2 hours 126/382 (33%) with rizatriptan (dosed based on weight) 94/388 (24%) with placebo	OR 1.52 95% CI 1.10 to 2.10 P <0.05	Small effect size	rizatriptan
RCT	791 children aged 6–17 years (randomised at Stage 2 following a placebo run-in period [Stage 1] – see Further information on studies)	Pain relief (defined as reduction in headache pain from moderate or severe to mild or no pain on the 5-Face Pain Scale) at 2 hours 220/382 (58%) with rizatriptan (dosed based on weight) 204/388 (53%) with placebo	OR 1.22 95% CI 0.91 to 1.63		Not significant
Nausea
RCT	791 children aged 6–17 years (randomised at Stage 2 following a placebo run-in period [Stage 1] – see Further information on studies)	No nausea at 2 hours 329/381 (86%) with rizatriptan (dosed based on weight) 303/388 (78%) with placebo	OR 1.70 95% CI 1.16 to 2.50 P <0.01	Small effect size	rizatriptan